European Medicines Agency to review risdiplam for use in spinal muscular atrophy

The Agency previously granted PRIME (priority) designation to this ‘Survival of Motor Neuron 2 (SMN2) splicing modifier, thus providing a pathway for its accelerated evaluation. The JEWELFISH, FIREFISH and SUNFISH studies provide evidence base to support licensing application.

Source:

PharmaTimes